Global Transcriptome Sequencing Based on RNA-seq Market Growth (Status and Outlook) 2023-2029

Global Transcriptome Sequencing Based on RNA-seq Market Growth (Status and Outlook) 2023-2029

The global Transcriptome Sequencing Based on RNA-seq market size is projected to grow from US$ 2642.3 million in 2022 to US$ 6045.8 million in 2029; it is expected to grow at a CAGR of 12.6% from 2023 to 2029.

United States market for Transcriptome Sequencing Based on RNA-seq is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.

China market for Transcriptome Sequencing Based on RNA-seq is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.

Europe market for Transcriptome Sequencing Based on RNA-seq is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.

Global key Transcriptome Sequencing Based on RNA-seq players cover Thermo Fisher Scientific, Illumina, QIAGEN (Exiqon), Agilent Technologies, Roche, GE Healthcare, Bio-Rad Laboratories and Fluidigm, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2022.

Transcriptome sequencing, also known as RNA sequencing (RNA-seq), is a high-throughput sequencing technique used to analyze and quantify the entire set of RNA molecules (transcripts) present in a cell or tissue sample.

LPI (LP Information)' newest research report, the “Transcriptome Sequencing Based on RNA-seq Industry Forecast” looks at past sales and reviews total world Transcriptome Sequencing Based on RNA-seq sales in 2022, providing a comprehensive analysis by region and market sector of projected Transcriptome Sequencing Based on RNA-seq sales for 2023 through 2029. With Transcriptome Sequencing Based on RNA-seq sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Transcriptome Sequencing Based on RNA-seq industry.

This Insight Report provides a comprehensive analysis of the global Transcriptome Sequencing Based on RNA-seq landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Transcriptome Sequencing Based on RNA-seq portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Transcriptome Sequencing Based on RNA-seq market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Transcriptome Sequencing Based on RNA-seq and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Transcriptome Sequencing Based on RNA-seq.

This report presents a comprehensive overview, market shares, and growth opportunities of Transcriptome Sequencing Based on RNA-seq market by product type, application, key players and key regions and countries.

Market Segmentation:

Segmentation by type
High-throughput
Low-throughput

Segmentation by application
Pharmaceutical and Biotechnology
Academic Research and Government Institutes
Hospitals and Diagnostic Centers

This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Thermo Fisher Scientific
Illumina
QIAGEN (Exiqon)
Agilent Technologies
Roche
GE Healthcare
Bio-Rad Laboratories
Fluidigm

Please note: The report will take approximately 2 business days to prepare and deliver.